ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / AVTR
BIO (62) TXG (59) BRKR (54) RVTY (65) ⌘ Pro Terminal →

Avantor Inc. (AVTR) — RQD Stock Rating Cockpit

$15.61 -2.74% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.50

Avantor Inc. (AVTR) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $10.88B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AVTR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AVTR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Avantor Inc. (NYSE: AVTR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $15.61 (-2.74% 1D, market cap $10.88B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, AVTR ranks #194 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AVTR compare to BIO and TXG in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), AVTR carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 32.7%, and ROIC of -2.1%. By comparison, BIO (Bio-Rad Laboratories Inc.) holds a C grade (62/100 RQD, P/E 13.5x, ROIC 0.5%, cap $9.95B) and TXG (10x Genomics Inc.) posts a C- grade (59/100 RQD, P/E N/A, ROIC -5.7%, cap $9.13B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while RVTY leads on capital efficiency (3.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AVTR?
▼

Per AVTR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001722482), Avantor Inc. generated $6.55B in revenue (-3.4% YoY), -$530.2M in net income, and $495.0M in free cash flow against $11.79B in total assets and $3.92B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $15.50 (-0.68%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 7.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510056
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk D
Cash (10)Whales (15)SEC (9)Macro (11)CEO (11)
Each axis scored 0–20
12M PRICE TARGET CONE-0.9% Base Target
$18 Bull$15 Base$12 Bear
📬 FREE AVTR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AVTR)Realized 20D OHLCV Swing Band: ±6.3%
Deterministic 5-Pillar Attribution (56/100 Composite)
🔍 WHY AVTR SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (27% of score)

20D Institutional Volume Accumulation (±6.3% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (20% of score)

FRED Regime × Technicals: 82% of 52W Range • RSI-14 at 48.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk9/20 pts (-11 pt drag)

Balance-sheet & 10-K footnote risk deducts 11 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
64
Grade C+$15.70+9.9% Next Q
Q2 (-2Q)
61
Grade C$17.26-3.3% Next Q
Q3 (-1Q)
59
Grade C$16.69-6.5% Next Q
Current
56
Grade D+$15.61-0.4% Hist 90D α
Trajectory: C+ (64) → D+ (56)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the AVTR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 56/100 (D+) score, AVTR faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.96% YoY Shares) — any gross margin slip below 30.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($15.62) or 200D SMA ($11.26) invalidates the momentum regime and cuts Target Base ($15.47) toward Bear Floor ($12.07).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AVTR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AVTR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 56%NO 44%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
48.330 Oversold · 70 Hot
ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)
1.88>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE82% OF RANGE
L: $7$15.61H: $17
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: CRQD 26 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on AVTR

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (50)

-2.1% ROIC with 32.7% gross margin and 4.38% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (45)

Altman-Z 1.88 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (62)

26/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like AVTR
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
Bear Case: What Could Go Wrong
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AVTR)

  • ✓Walkthrough of AVTR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AVTR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +95.37%🛡️ HOLDING TREND SUPPORT
2026-11-03O $16.68H $16.68L $15.61C $15.61VOL 9.73M
RES: $17.87SUP: $15.54SMA50: $15.62SMA200: $11.26
$18.15$15.24$12.33$9.43$6.52RES $17.87SUP $15.54$15.612026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AVTR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AVTR Butterfly Map → + Track AVTR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
23.9%/yr Implied 5Y Growth

vs. -3.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AVTR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AVTR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AVTR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AVTR)

Health Care Rank #194 of 1015 ⚔️ BIO vs AVTR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AVTR vs. BIO, TXG, BRKR, RVTY)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Avantor Inc. (AVTR) ranks #194 by composite RQD confidence (56/100, grade D+) and #98 by equity capitalization ($10.88B). Within this direct 5-issuer industry benchmark cohort, BIO leads on earnings valuation at 13.5x trailing P/E, while RVTY leads on capital efficiency and profitability with 3.1% ROIC and — gross margin. RVTY currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with AVTR at 56/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AVTR ACTIVE
Avantor Inc.
D+ 56/100 — 32.7% -2.1% -2.74% $10.88B Benchmark Subject
BIO
Bio-Rad Laboratories Inc.
C 62/100 13.5x 51.9% 0.5% -1.62% $9.95B /bio-vs-avtr →
TXG
10x Genomics Inc.
C- 59/100 — 69.1% -5.7% -12.09% $9.13B /txg-vs-avtr →
BRKR
Bruker Corporation
D+ 54/100 — 45.9% 1.3% -2.42% $8.70B /brkr-vs-avtr →
RVTY
Revvity Inc.
C 65/100 76.7x — 3.1% -3.44% $17.52B /rvty-vs-avtr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001722482 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Avantor Inc. (AVTR) reported GAAP revenue of $6.55B (-3.4% vs. FY2024 revenue of $6.78B , and -6.0% cumulative change since FY2023) , GAAP net income of -$530.2M, operating cash flow of $623.8M, and free cash flow of $495.0M (-28.5% YoY). On the balance sheet, AVTR closed FY2025 with $11.79B in total assets against $3.92B in total debt (Altman Z-Score: 1.88, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $6.55B -$530.2M $623.8M $495.0M $11.79B $3.92B
FY2024 (FY) 2024-12-31 $6.78B $711.5M $840.8M $692.0M $12.11B $3.23B
FY2023 (FY) 2023-12-31 $6.97B $321.1M $870.0M $556.5M $8.36B $1.96B

3. AVTR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AVTR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Avantor Inc. (NYSE: AVTR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $15.61 (-2.74% 1D, market cap $10.88B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, AVTR ranks #194 in composite RQD confidence.

How does AVTR compare to BIO and TXG in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), AVTR carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 32.7%, and ROIC of -2.1%. By comparison, BIO (Bio-Rad Laboratories Inc.) holds a C grade (62/100 RQD, P/E 13.5x, ROIC 0.5%, cap $9.95B) and TXG (10x Genomics Inc.) posts a C- grade (59/100 RQD, P/E N/A, ROIC -5.7%, cap $9.13B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while RVTY leads on capital efficiency (3.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AVTR?

Per AVTR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001722482), Avantor Inc. generated $6.55B in revenue (-3.4% YoY), -$530.2M in net income, and $495.0M in free cash flow against $11.79B in total assets and $3.92B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AVTR trading relative to its 50-day, 200-day, and 52-week technical levels?

AVTR last traded at $15.61 (-2.74% on volume of 9,404,283 shares), positioning the stock -0.06% below its 50-day simple moving average ($15.62) and +38.63% above its 200-day simple moving average ($11.26). Across its 52-week range of $7.26 to $17.45, AVTR sits at the 81.9% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±6.3% ($14.63 to $16.59).

Direct Sub-Reports: AVTR RQD Cockpit AVTR 12M Forecast AVTR Earnings & Move AVTR Dividends & DRIP AVTR Insiders & 13F AVTR Whale Options AVTR Profit Sankey AVTR News & Why
ROARABLE RATING BRIEF • RQD 56/100 (D+) ✓ SEC XBRL & RQD VERIFIED

AVTR — Avantor Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Avantor Inc. (AVTR) earns a live Roarable RQD composite score of 56/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $15.61 (-2.74% 1D, market capitalization $10.88B).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of -2.1%, gross margin of 32.7%, operating margin of -3.8%, and free cash flow yield of 4.38%.
  • Whale 13F & Options Flow (15/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (9/20): Incorporates a 1.01x equity beta, Altman Z-Score of 1.88, Piotroski F-Score of 5/9, and Debt/Equity of 0.70x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Avantor Inc. Is a NYSE-listed issuer classified under the Health Care sector and Biotechnology: Laboratory Analytical Instruments industry,. The source data provides a market capitalization of $11.3B. Gross margin is 32.7% per the market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Avantor Inc. (AVTR) reported $6.55B in annual revenue (up from $6.78B in FY2024, -3.4% YoY) and -$530.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($6.97B revenue, $321.1M net income) through FY2025, AVTR scaled operating cash flow to $623.8M and free cash flow to $495.0M, backed by $11.79B in total assets against $3.92B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 56/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of 4.38% and institutional whale pillar of 15/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $7.26 – $17.45 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Investors must weigh current valuation against -3.8% operating margins and a 1.01x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context provided is Health Care / Biotechnology: Laboratory Analytical Instruments.

  • Key Question #1: Can AVTR sustain or expand its -3.8% operating margin and -2.1% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $6.55B and free cash flow of $495.0M, how will capital allocation balance growth reinvestment against $3.92B in total debt?
  • Key Question #3: How sensitive is AVTR's 31.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.01x)?

AVTR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Avantor Inc. (AVTR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AVTR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AVTR Bull vs. Bear Conversation Board — What's Your Call at $15.61?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AVTR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AVTR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $19.10 (+19.0%)
📌 Pinned Debate

Institutional whale flow scores 18/20 and the FCF yield of 4.38% shows the business still generates cash relative to its market value.

Don't sleep on AVTR's setup in Health Care. Institutional whale flow scores 18/20 and the FCF yield of 4.38% shows the business still generates cash relative to its market value.. Beta of 1.01 means it moves fast when momentum turns, and the 5-pillar RQD gauge (56/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@ShortSeller_Dan Fair point on 31.0x forward P/E, but you're ignoring the forward operating leverage in Biotechnology: Laboratory Analytical Instruments. If gross margin (32.7%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $13.00 (-19.0%)
Spot @ $16.05

ROIC of -2.1%, FY 2025 net loss of -$530.2M, and debt rising to $3.92B against an Altman Z of 1.88 point to a weak return profile and

I respect the product at Avantor Inc., but the stock at $16.05 is a different story. ROIC of -2.1%, FY 2025 net loss of -$530.2M, and debt rising to $3.92B against an Altman Z of 1.88 point to a weak return profile and balance-sheet strain.. FCF yield is 4.38% and RQD sits at 56/100 (D+) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%